Last reviewed · How we verify

Vascepa — Competitive Intelligence Brief

Vascepa (ICOSAPENT ETHYL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: icosapent ethyl. Area: Metabolic.

marketed icosapent ethyl Diacylglycerol O-acyltransferase 1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Vascepa (ICOSAPENT ETHYL) — Amarin Pharms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vascepa TARGET ICOSAPENT ETHYL Amarin Pharms marketed icosapent ethyl Diacylglycerol O-acyltransferase 1 2012-01-01
Vascepa Vascepa University of Louisville marketed Diacylglycerol O-acyltransferase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (icosapent ethyl class)

  1. Amarin Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vascepa — Competitive Intelligence Brief. https://druglandscape.com/ci/icosapent-ethyl. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: